Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma
| Autor: | Matthias Volkenandt, Susanne Rötzer, Jörg Boettjer, Axel Hauschild, Thomas Vogt, Ruthild Linse, Friederike Egberts, Thomas Eigentler, Sarah Heinze, Norbert H. Brockmeyer, Konstanze Spieth, Axel Hinzpeter, Martin Schaefer, Wolfgang Tilgen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Skin Neoplasms Immunology Alpha interferon Antineoplastic Agents Personality Disorders behavioral disciplines and activities Risk Factors Multicenter trial Humans Immunology and Allergy Medicine Risk factor Psychiatry Melanoma Depression (differential diagnoses) Aged Psychiatric Status Rating Scales Pharmacology Depressive Disorder Mood Disorders business.industry Incidence (epidemiology) Beck Depression Inventory Interferon-alpha Middle Aged Clinical trial Mood Female business |
| Zdroj: | Journal of Immunotherapy. 33:106-114 |
| ISSN: | 1524-9557 |
| DOI: | 10.1097/cji.0b013e3181b8bdb9 |
| Popis: | The purpose of the present study was to evaluate the incidence, spectrum and extent of psychiatric symptoms in patients with malignant melanoma (MM) before and during adjuvant treatment with interferon-alpha (IFN-alpha). 850 patients with cutaneous MM ofor =1.5 mm tumor thickness received standard low-dose IFN-alpha 2a in this prospective multicenter trial of the Dermatologic Cooperative Oncology Group (DeCOG). Psychiatric symptoms were evaluated at baseline and after 3, 6, and 12 months with the Beck Depression Inventory (BDI) and the Symptom Check List 90-Revised (SCL 90-R). In all, 282 patients completed all questionnaires. Mean BDI depression scores increased significantly during the first 6 months of IFN-alpha treatment (Por =0.001), followed by a mild but not significant decrease. Also mean SCL 90-R scores increased significantly during the first 3 months of adjuvant treatment with IFN-alpha (Por =0.001) and remained elevated until month 12 (Por =0.001). Only 5% developed BDI scores10, indicating a clinically significant depressive syndrome and only 1.4% reached a BDI scoreor =18, indicating a moderate to severe depressive syndrome. Patients, who dropped-out early from psychiatric reasons, had significantly increased BDI and SCL-90R scores at baseline. Women scored higher in both scales before and during treatment if compared with men. In conclusion, adjuvant treatment with IFN-alpha was associated with a significant increase of BDI- and SCL 90-R scores. A higher pretreatment depression score was found to be a risk factor for an early drop-out during therapy. Pretreatment screening and an interdisciplinary care of the patients is recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|